Davide Melisi

заклад освіти: Неапольський університет імені Фрідріха II

рід діяльності: дослідник

Серія

Тут нічого немає

Створити нову серію

Твори

Тут нічого немає

Створити новий твір

Статті 61

Дата

Заголовок

Автори

2020-06-12

Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer

Valeria Merz, Camilla Zecchetto, Domenico Mangiameli, Geny Piro, Michela Deiana, Maria Teresa Valenti, Vita Fedele, Davide Melisi
2020-07-07

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial

Davide Melisi
2020-10-09

Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

Valeria Merz, Camilla Zecchetto, Davide Melisi
2020-11-08

HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies

Serena Contarelli, Davide Melisi
2020-11-20

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib

Ian M Silverman, Antoine Hollebecque, Luc Friboulet, Luis Feliz, Camilla Zecchetto, Davide Melisi
2020-09-04

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial

Marina Gaule, Davide Melisi, Alessandro Esposito, Claudio Bassi, Francesca Simionato, Camilla Zecchetto, Valeria Merz, Mirko D'Onofrio, Giuseppe Malleo, Luca Landoni, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Roberto Salvia
2019-09-27

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

Valeria Merz, Chiara Cavallini, Aldo Scarpa, Davide Melisi
2019-07-24

Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Laura Maggino, Chiara Nessi, Davide Melisi, Claudio Bassi, Francesca Simionato, Camilla Zecchetto, Valeria Merz, Mirko D'Onofrio, Giuseppe Malleo, Luca Landoni, Giovanni Marchegiani, Luca Casetti, Massimiliano Tuveri, Salvatore Paiella, Roberto Salvia, Erica Secchettin, Deborah Bonamini
2019-11-13

Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer

Alessandro Cavaliere, Valeria Merz, Simona Casalino, Camilla Zecchetto, Francesca Simionato, Hayley Louise Salt, Serena Contarelli, Raffaela Santoro, Davide Melisi
2019-03-18

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

Davide Melisi
2019-09-03

Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Davide Melisi
2019-09-05

Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma

Hideo Tomihara, Manuela Iezzi, Isabella Manni, Frederick Scott Robinson, Ya'an Kang, Antonella Iuliano, Donatella Del Bufalo, Diego di Bernardo, Davide Melisi, Gennaro Ciliberto, Luca Cardone, Jason Fleming, Giulio F Draetta
2018-02-01

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer

Carmine Carbone, Valeria Merz, Davide Melisi, Giampaolo Tortora
2018-02-01

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Valentina Fanotto, Francesco Leone, Samantha Di Donato, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone, Davide Melisi, Caterina Vivaldi, Lorenzo Gerratana, R Filippi, Nicola Silvestris, Riccardo Giampieri, Mario Scartozzi
2018-04-01

MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity.

Davide Melisi, Giampaolo Tortora
2018-03-26

Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy

Luisa Carbognin, Isabella Sperduti, Davide Melisi, Lisa Salvatore, Emilio Bria, Giampaolo Tortora
2018-03-16

Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.

Carmine Carbone, Giampaolo Tortora, Davide Melisi, Geny Piro, Raffaela Santoro
2018-03-15

The curious case of Gαs gain-of-function in neoplasia

Giulio Innamorati, Davide Melisi, Claudio Bassi, Maria Teresa Valenti, Luca Dalle Carbonare, Luca Giacomello
2018-10-25

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance

Geny Piro, Davide Melisi, Carmine Carbone, Giampaolo Tortora
2018-10-23

Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data

Davide Melisi, Claudio Bassi, Giuseppe Malleo, Giovanni Marchegiani, Roberto Salvia, Erica Secchettin
2018-12-05

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes

Francesco De Sanctis, Giulio Fracasso, Silvia Sartoris, Giada Mondanelli, Carmine Carbone, Davide Melisi, Rita A Lawlor, Aldo Scarpa, Alessia Lamolinara, Manuela Iezzi, Matteo Fassan, Угур Шахін, Fulvia Vascotto, Bruce R Blazar, Keli L Hippen
2018-04-10

Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results

Salvatore Paiella, Roberto Salvia, Tommaso Pollini, Luca Landoni, Alessandro Esposito, Giovanni Marchegiani, Giuseppe Malleo, Laura Maggino, Stefano Andrianello, Davide Melisi, Claudio Bassi, Mirko D'Onofrio, Luca Casetti, Massimiliano Tuveri, Aldo Scarpa, Erica Secchettin, Deborah Bonamini
2018-12-11

Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study

Valentina Fanotto, Lorenzo Fornaro, Lorenza Rimassa, Samantha Di Donato, Francesco Leone, Federico Nichetti, Antonio Avallone, Davide Melisi, Lorenzo Gerratana, Nicola Silvestris
2018-08-01

CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy

Nicolò Cardobi, Davide Melisi
2018-11-17

Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin

Davide Melisi
2017-08-31

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

Valentina Fanotto, Francesco Leone, Samantha Di Donato, Filippo Pietrantonio, Francesca Battaglin, Antonio Avallone, Davide Melisi, Caterina Vivaldi, Lorenzo Gerratana, R Filippi, Nicola Silvestris, Gianluca Tomasello, Riccardo Giampieri, Mario Scartozzi
2017-08-08

Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension

Alessandra Ghigo, Immacolata Andolfo, Davide Melisi, Christophe Leboeuf, Anne Janin
2017-04-20

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Davide Melisi, Oronzo Brunetti, Francesco Leone, Donatella Marino, Marco Puzzoni, Nicola Silvestris
2017-04-28

A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma

Carmine Carbone, Giuseppe Malleo, Davide Melisi, Claudio Bassi, Giampaolo Tortora, Francesca Simionato, Camilla Zecchetto, Valeria Merz, Aldo Scarpa
2017-09-12

EMT and Treatment Resistance in Pancreatic Cancer

Davide Melisi, Carmine Carbone
2017-09-30

Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis

Alessandra Ghigo, Immacolata Andolfo, Davide Melisi, Christophe Leboeuf, Anne Janin
2017-03-28

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.

Caitlyn Solem, Davide Melisi, Richard A Hubner

Human - wd:Q38589634

Ласкаво просимо до Inventaire

the library of your friends and communities

докладніше